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Recently, vector-borne parasitic diseases such as leishmaniasis have been emerged or re-
emerged in many geographical areas and resulted in global health and economic concerns
that involve humans, domestic animals and wild life. The ecology and epidemiology of
leishmaniasis are affected by the between host, reservoir and vector (human, animal and
sandﬂy) and the environment. Important drivers for the emergence and spread of leish-
maniasis include environmental factors such as alterations in temperature and water
storage, irrigation habits, deforestation, climate changes, immunosuppression by HIV or
organ transplant, development of drug resistance, increase traveling to endemic regions
and dog importation. War, poor socio-economic status and low level household are also
major contributors to the spread of this disease. Health education via the public media and
training should be implemented by international organizations and governmental agencies
in collaboration with research institutions. Fully protection during transmission season,
using bednets and insecticides and reservoirs' control should be also mentioned in the
planning. Based on the ﬁndings of the recent studies and high prevalence of leishmani-
asis, it is concluded that serious public health monitoring should be considered.1. Leishmaniasis
Leishmaniasis, a vector-borne disease that is caused by
several species of obligating intra-macrophage protozoan para-
site [1,2]. This neglected disease is endemic in large areas of the
tropics, subtropics and the Mediterranean basin. The vector-
borne parasitic disease is characterized by diversity and
complexity [3]; it is caused by about 20 Leishmania species and
is transmitted to humans by more than 30 different species of
phlebotomine sandﬂies [4,5]. This infectious disease has
diverse clinical manifestations, including cutaneous, diffuse
cutaneous, mucocutaneous (espundia), visceral (kala-azar),
post kala-azar dermal leishmaniasis (PKDL) and recidivans [6].
Leishmaniasis is a public health problem in more than 88
countries [7,8]. The estimated world prevalence of all forms of
the disease is 12 million, with 1.5–2 million added new cases
annually of cutaneous, and 500 000 cases of visceral
leishmaniasis and about 50 000 deaths from the disease eachyear [9,10], a death toll that is surpassed between the parasitic
diseases only by malaria [11].
So far, leishmaniasis research has considered only a single or
a limited number of parameters, and has majority been con-
ducted in Leishmania-endemic areas. There is thus an urgent that
needs to conduct more ambitious researches on the clinical,
environmental, co-infections and resistance predictors of
Leishmania in endemic areas. In these times leishmaniasis
shows a wider geographic distribution than before; it is still one
of the world's most neglected diseases affecting largely the poor
and developing countries.
The increase in leishmaniasis incidence and prevalence is
mainly attributed to several risk factors that are clearly man
made and the most important factors have been mentioned in
this review. Generally, environmental conditions, socio-eco-
nomic status, demographic and human behaviors pose major
risks for human leishmaniasis [12,13]. Also increase in the
worldwide incidence of leishmaniasis is mainly attributed to
the increase of several risk factors that are clearly man made
and such as great migration, deforestation, urbanization and
immunosuppression. The environment and the population
movements, probably lead to alterations in the number, range
and density of the vectors and reservoirs and consequently,
may increase human exposure to infected sandﬂies [14].C-ND license (http://
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outbreak occurs during harvesting seasons [15]. Following
agricultural development in the area, a large number of labor
migrants from the highlands were moved to the endemic areas
in the late 1970 for crop harvesting. This led to spread of
visceral leishmaniasis, which resulted in high morbidity and
mortality [16].
2. Vector distribution
Approximately, 600 species of Phlebotominae are known,
most of which belong to the genera Phlebotomus in the Old
World and Lutzomyia in the New World. Less than 10% of these
species act as disease vectors and only 30 species of these are
important in the public health. Phlebotomus is the dominant
genus in the Palearctic. It includes the earthly ecoregions of
Europe, Asia, northern Africa, the northern and central parts of
the Arabian Peninsula and extending to other regions of the Old
World. Phlebotomus are of little importance in North America
but Lutzomyia is the main genus in Latin America and is found
over large regions [17]. The spread and distribution of sandﬂies
largely determines the occurrence of leishmaniasis. In general,
Phlebotomus (the Old World sandﬂy species) is seen in desert
or semi-arid ecosystems [18]. Some of the species breed in
peridomestic situations and enter human housing; whereas
Lutzomyia (the New World sandﬂy species) transmit the
leishmaniasis in forest habitation and occur in humans near
the forest. Usually, sandﬂies are seen around human dwelling
and breed in speciﬁc organic wastes including to dung, feces,
rodent holes, leaf litter and the cracks and crevices in the
walls having high temperature and humidity. It is noted that
the distribution pattern of sandﬂies and leishmaniasis appears
to be changing [17].
3. Organ transplant
Natural transmission of the Leishmania species is occurred
by phlebotomine sandﬂies of the genus Phlebotomus or Lutzo-
myia. However, different forms of leishmaniasis could also be
transmitted by organ transplantation and blood transfusions by
needle sharing among intravenous drug addicts [19]. Leishmania
species are obligated intracellular parasites in the mammalian
host, where they exist as multiplicative “procyclic”
promastigotes and infective “metacyclic” promastigotes and
they are living mainly in the phagolysosome of macrophages.
Cell-mediated immunological mechanisms are responsible to
control the infection in the infected cells of host [20]. Acquired
resistance to leishmaniasis is mediated by T cells. CD4+
lymphocytes are crucial for resistance and CD8+ are more
involved in memory than as effector cells. The
immunosuppressive drugs prevent T-cell proliferation and
activation, therefore alter the defense mechanisms against
Leishmania species in transplant recipients [21,22].
Although leishmaniasis is a rare disease among transplant
patients, it requires clinical evaluation for several reasons. Many
organ transplantations are performed annually in the world,
while the transplant recipients often travel to endemic leish-
maniasis countries. Thus, the risk of developing leishmaniasis
among the transplant recipients that travel to an endemic region
following transplantation, which has been reported in several
cases [23,24]. Moreover, there is limited information about
leishmaniasis among physicians. Leishmaniasis usually occursas a late complication after transplantation, with a median
delay of 18 months between transplantation and onset of
disease [25,26]. Diagnosis of the clinical signs of leishmaniasis
in the transplanted recipients can be delayed for several
months or it might be misdiagnosed [27–29]. Visceral
leishmaniasis should be considered in the differential diagnosis
from other symptoms occurring after organ transplantation
including fever and pancytopenia, especially in endemic
regions and in organ recipients who travel to regions where
the disease is endemic.
4. Drug resistance
The current control strategies for leishmaniasis rely on
reservoir and vector control, active case detection and treatment
of their disease and the use of insecticides [7,30] and the anti-
leishmanial vaccines are still to be developed. Treatment stra-
tegies of the infected dogs are not effective control manners,
because relapses of disease are seen frequently and dogs can
regain infectivity weeks after treatment, despite being clinically
cured [31]. Moreover, the extensive veterinary use of
leishmaniasis drugs might lead to resistance in parasites.
Gavgani et al. demonstrated that a new control approach was
the use of deltamethrin-treated collars which reduced the risk
of infection in dogs by 54% and in children by 43% [32].
Early detection, diagnosis and treatment are crucial for indi-
vidual patients and for the community. Untreated leishmaniasis
patients are as reservoir for parasites and therefore provide disease
transmission in anthroponotic leishmaniasis regions [9,30,33]. The
sodium stibogluconate, meglumine antimoniate and pentamidine
have been the ﬁrst-line drugs for human leishmaniasis in many
countries of the world for more than 70 years [34]. Pentavalent
antimonials are toxic drugs with frequent adverse side effects,
such as cardiac arrhythmia and acute pancreatitis and they are
life-threatening in some cases. Patients under the age of two
and age over 45 years with symptoms of advanced disease and
with severe malnutrition are at higher risk of death during treat-
ment with antimonial compounds owing to drug toxicity, slow-
ness of drug action or a combination of these factors [35].
However, miltefosine, paramycin and liposomal amphotericin
B, alone or in combination became the drug of choice in recent
decades to prevent the emergence of resistance [36]. In reality,
antimonials are still applied in many poor countries.
Conventional amphotericin B has changed antimonials as the
ﬁrst-line treatment for disease in some countries that treatment
failure rates are high [37]. Fever, chills and rigor are almost
universal adverse effects following treatment with conventional
amphotericin B, and life-threatening side effects including hy-
pokalemia and nephrotoxicity. In the ﬁrst-dose of this drug,
anaphylaxis is not uncommon. Moreover, conventional ampho-
tericin B is costly and requires a complicated regimen (15 slow
infusions on alternate days). Liposomal amphotericin B is
considered by many experts as the best existing drug against
visceral leishmaniasis, and is used as the ﬁrst-line choice in the
United States and Europe. Until recently, its use in the devel-
oping countries was prevented by its high market price [38,39].
Miltefosine is a teratogenic drug and its use is thus strictly
forbidden in pregnant women or in women who could become
pregnant within two months of treatment. It has been seen that
miltefosine has a long half-life and parasite resistance is easily
induced [40]. Non-adherence to the recommended regimen could
lead to prevalent parasite resistance [41]. The increasing use of
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increase the development of miltefosine resistance.
Combination therapy is the proposed option forward to
increase efﬁcacy of treatment, prevent the development of
drug resistance, reduce treatment duration and maybe decrease
treatment cost [42].
5. Travel to endemic areas
Leishmaniasis is increasingly reported among travelers
returning from tropical and subtropical regions, and the broad
clinical spectrum and the limited science of the disease among
clinicians and travelers often lead to a wrong initial diagnosis
[43]. Limited data exists on the incidence of leishmaniasis in the
travelers in most developed countries, because the number of
exposed travelers is often unknown, the disease is usually
misdiagnosed and is self-healing. The occurrence of imported
cases has increased, because more cases occur due to the
increasing number of travelers to endemic countries. However, a
few cases of travelers to endemic countries where leishmaniasis
is prevalent that have been mentioned in the literature [44,45].
Alcais et al. reported that the risk of leishmaniasis was 3–10
times higher in the migrants than in the local population.
Therefore, the travelers may be at a higher risk of developing
leishmaniasis than the natural people [46].
While leishmaniasis has always been endemic in the Medi-
terranean area, this disease has been seen in northern latitudes
including United States of America, Canada and Germany, from
which sandﬂy vectors are present in very low densities [47–49].
Desjeux explained that the maximum northern latitude for
sandﬂy survival, which is speculated to move further to the
North, beyond Germany because of global warming [50]. This
can be explained by dog importation or travel to the endemic
countries. Nevertheless, Duprey et al. observed that vertical
transmission of canine leishmaniasis has occurred in the
eastern United States of America and Canada imported from
Europe [49]. However, vertical transmission from bitch to
puppy has rarely been seen [51]. Increase in the number of
travels and immigration of dogs have signiﬁcantly increased
the incidence of this disease in the non-endemic countries
[52,53]. Furthermore, in areas where the infection is not
considered endemic, diagnosis may be delayed because of a
low index of suggestion or by unusual presentation in
immunosuppressed subjects.
6. Canine leishmaniasis
Canine leishmaniasis is a vector-borne parasitic disease of
dogs, occurring in the entire world, except Oceania [54].
Transportation of dogs from areas of canine leishmaniasis
endemicity has resulted in widespread of disease to areas
where infection has been absent [55–57], and this topic may
results in new epidemiological prevalence in the world. The
risk of canine leishmaniasis transmission is dependent on
sandﬂies, also venereal and transplacental transmission should
be seriously considered [58].
7. Leishmania/HIV co-infection
World Health Organization reported that the incidence of
human visceral leishmaniasis has displayed a sharp increasesince the early 1990s in Mediterranean countries, mostly under
the inﬂuence of human immunodeﬁciency virus (HIV) co-
infection [59]. This phenomenon has occurred particularly in
the coastal regions of Spain, France and Italy [60,61], where
the incidence of ofﬁcially reported visceral leishmaniasis cases
almost doubled from 1987 up to 2004 [62,63]. Leishmania/HIV
co-infections have worldwide distribution and have been
recorded in 35 countries. Cruz et al. reported that there were
Leishmania parasites in the discarded syringes [19]. Desjeux and
Alvar also demonstrated that widespread needle transmission of
Leishmania infantum was inferred in southwest Europe [64].
Gabutti et al. mentioned that the highest rates of worldwide
Leishmania/HIV co-infection are from Europe, where 85% of
the cases were from the southwest; 71% of which were isolated
from the intravenous drug users [65]. Visceral leishmaniasis/HIV
co-infection is a serious phenomenon that leads to death.
Although, the highly active antiretroviral therapy for HIV has
diminished the number of these co-infection cases and improved
the survival rates [66,67]. The mean time from signs onset to
diagnosis has been reported 3 months [68]. This delay resulted
often from physicians’ failure to consider the diagnosis. Malik
et al. noted the importance of looking at rare imported
diseases over a long period so that emerging risk factors can
be identiﬁed [69].
The geographic distribution of leishmaniasis has prevalent in
the world, and the disease has been seen in countries in which
leishmaniasis was not previously endemic [50]. All form of
leishmaniasis including cutaneous, mucocutaneous, visceral
and recently leishmaniasis/HIV co-infection are widespread in
all of the world [50]. According to the World Health
Organization, visceral leishmaniasis has often been known as
a disease of children [50]. However, visceral cases are recently
reported in adults too. This occurrence in age groups may be
explained by the increased proportion of Leishmania/HIV co-
infected individuals and partly by increased travel activities of
differently immunocompromised individuals. People traveling
to endemic countries should be aware about their increased
susceptibility to infection with Leishmania. However, travelers
should be recommended to wear suitable cloths, take repellents
and have mosquito nets to reduce the exposure to the sandﬂy,
and use collars impregnated with repellents for accompanying
dogs [47].
Seroprevalence data shows high endemicity in some Euro-
pean countries [70,71]. On the other hand, the evidently potent
associations between Leishmania seropositivity and traveling
to endemic countries, as risk factor is clearly associated with
prolonged residence in an endemic country. Migration, climate
change, contact with dogs and Leishmania/HIV co-infection
are the main factors driving the increased incidence and preva-
lence of leishmaniasis [30,50].
Climate changes might affect natural transmission of
Leishmania spp. by the bite of sandﬂies. On other hand, the
temperature and climate changes might affect on parasite
reproduction and proliferation and the abundances of the
sandﬂies and eventually on distribution of leishmaniasis [72].
A strong association between the cycle and the annual
incidence of visceral leishmaniasis has been reported by
Franke et al. in Brazil [73]. Spatio-temporal modeling of
the distributions of the leishmaniasis and their vector in
relation to climate change has previously been mentioned
[74].
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Whilst some reports have indicated that leishmaniasis is
associated with climate change, HIV/Leishmania co-infection,
environmental factors and domestic animals, little is known
about other household characteristics that associated with this
disease. Household design and construction material including
number of ﬂoors, number of rooms, dirt ﬂoor, damp earthen
ﬂoors and houses with cracked mud or thatched plastered house
walls are the common risk factors of leishmaniasis. Other risk
factors of the disease include presence of domestic animals such
as dogs, pigs and rodent and proximity to forested areas and
other regions where sandﬂies are aggregated [75–77].
Reithinger et al. indicated that household construction ma-
terials including brick walls and design such as number of rooms
or number of windows per person can signiﬁcantly inﬂuence
anthroponotic leishmaniasis risk. Household level and human
behavior may ultimately increase or decrease sandﬂy exposure.
However, greater density in terms of household members per
room and increasing the individual household members, in
contrast to increased number of household rooms with inside
walls and doors more likely increase and reduces exposure of the
household members' to sandﬂies respectively [78]. Thus, the
transmission risk of Leishmania is strongly dependent on the
presence of disease in other household members in the same
region, which is indicative of the short ﬂight range of
sandﬂies [79] and it is likely that a household with a high
proportion of people with leishmaniasis is ‘infectious’ to its
inhabitants from an epidemiological point of view.
Finally, it has been shown that reduction in vector exposure
can be highly successful in reducing the risk of leishmaniasis.
Screening of household windows and ceilings is effective in
reducing leishmaniasis [78]. The previous studies have
interestingly shown that this approach has been effective in
reducing malaria and other mosquito-borne infectious disease
too [80]. Intervention strategies to reduce sandﬂy vector contact
and implementation of provisional treatment modalities are
recommended to reduce leishmaniasis risk.
9. Social condition
Leishmaniasis, especially the visceral form, tends to affect
the poorest people and marginalized societies [81] particularly
those people that are close to water resources, live in humid
houses, and are in vicinity of accumulated rubbish, sewerage
and farms of livestock. Individuals in under-developed houses
for example mud or thatched rooms with cracked walls and low
socio-economic status have been found at risk for leishmaniasis
[82,83]. The recent risk factors contribute to the growth and
multiplication of sandﬂy. Other studies have shown that the
risk of leishmaniasis has been associated with mud house,
cattle density, presence of rodent, dog, other leishmaniasis
cases and poor socio-economic status [82,83] which may have
difﬁculties in accessing treatment [84]. However, infected
individuals may play an important role in sustaining
transmission in these areas and result in endemicity of
leishmaniasis in poor communities [85]. The role of domestic
animals mainly cattle in proximity of the houses has been
emphasized as a risk factor for leishmaniasis [86].
The risk of disease in those individuals which are living in
close contact to the asymptomatically infected individuals andleishmaniasis cases in the neighboring houses is signiﬁcantly high
[87]. A worse socio-economic status is associated with an
increased risk of seroconversion. It has also been conﬁrmed that
seroconversion and leishmaniasis are strongly associated [87]. In
addition, a strong association between the occurrence of a new
leishmaniasis case and the presence of asymptomatically
infected persons in the surrounding houses has been indicated.
Many studies have shown the use of bednets to be protective
against Leishmania infection [87,88]. Some sleeping habits such
as using bednet, sleeping under a cover and spraying inside
have been found protective [88]. However, seroconversion has
signiﬁcantly been found that it associated with household
spraying. Finally, investigation of the risk factors for this
disease is complex because of the leishmaniasis with unstable
transmission and because of the high number of latent infections
and infected animals for which validated markers is not present.
10. Environmental factors
The prevalence and development of leishmaniasis are largely
dependent on environmental factors and natural conditions. In
addition to the economic, social and cultural conditions, preva-
lence of leishmaniasis is inﬂuenced by ecological factors too
[89]. Vegetation area and climatic factors have important roles in
proliferation and growth process of sandﬂies and subsequent
outbreak of leishmaniasis. Also, improving vegetation types
and climate condition for growth and proliferation of rodents
that can transmit the disease could be suitable in declining the
leishmaniasis outbreaks [90]. It has been reported that
deforestation has led to an increase in leishmaniasis [74,91].
The forest has been shifted to other types of cultivation,
dispersed with patches of forest. With growth of the dog, fox
and rodent populations as reservoir hosts of this disease, the
prevalence of leishmaniasis has increased and the sandﬂy
vectors have become peridomestic [92].
Forest fragmentations, climatic variables, vegetation indices
and land surface temperature are important candidate predictors
for vector-borne diseases such as leishmaniasis [93–97]. Changes
in land coverage such as deforestation and continually replace
by farmland has an increasing risk for leishmaniasis [98].
Feliciangeli et al. indicated that risk of leishmaniasis has
traditionally been associated with working in or near forest
[99]. Recent studies in Latin American countries have shown
that transmission of leishmaniasis has been shifting from
sylvatic and forestial areas to domestic and rural settlements
[100,101]. Risk of cutaneous and visceral leishmaniasis has been
found to be associated with environmental factors such as land
use, temperature and vector density [98,102–104].
Kassiri et al. showed a correlation between the gender and
incidence of leishmaniasis and the disease was seen more in
men than women [105]. Occurrence of higher prevalence in men
than women is logic, because the men work or sleep in
populated and infected environments and is exposed to the
infected vectors more than women [106]. Many investigations
have found that gender difference, attributable to hormonal
effects, has been observed in some other parasitic diseases
too [107]. It is more likely that men are exposed to sandﬂies
in ﬁelds and other open areas more than women; probably
this issue equally or more importantly than the sex hormones
may affect the establishment and the course of parasitic
diseases [108,109].
A. Oryan, M. Akbari/Asian Paciﬁc Journal of Tropical Medicine 2016; 9(10): 925–932 92911. Vaccines
Leishmaniasis, especially its visceral form, affects poor
countries, generally in remote rural areas. The disease is mostly
endemic in the poorest and least developed countries in the
world [110]. The high direct and indirect costs of the disease such
as the costs of diagnosis, treatment and loss of household
income, should be paid by patients [111–113]. The commitment
of the governments of the developing countries to precede a
regional visceral leishmaniasis elimination program is
necessary. The existing methods of vector or reservoir control
cannot be used effectively by poor countries due to their high
cost and problems with their operating and administrative
programs [114,115]. Furthermore, toxicity of the available drugs
including pentavalent antimonials, the current drugs of choice
in these countries, and increasing parasite resistance underline
the need for an effective preventive vaccine that would protect
the susceptible subjects against leishmaniasis and could also
interrupt the transmission cycle of parasite [42,111,115].Table 1
Risk factors of emergence and re-emergence leishmaniasis and their
effects.
Risk factor Effects
Organ transplant Prescription immunosuppressive drugs/
prevent T-cell activation and
proliferation of parasite/reduce the
defense mechanisms against
intracellular parasites
Resistance
of drugs
Widespread veterinary use of visceral
leishmaniasis drugs/use antimonials in
poor countries/increasing use of
miltefosine for canine leishmaniasis
Travel to
endemic areas
Increasing travel to tropical and
subtropical countries (endemic area)/
dog importation to non-endemic regions
Canine leishmaniasis Transportation of dogs from regions of
canine leishmaniasis endemicity to non-
endemic area/infecting sandﬂies and
venereal and transplacental transmission
in dogs in non-endemic area
Leishmania/HIV
co-infections
Prevalence of human immunodeﬁciency
virus (HIV)/existing Leishmania in
discarded syringes of addict persons/
incidence visceral leishmaniasis in
adults in addition to children
Climate change Temperature and environmental
variation on the abundances of the
sandﬂies
Household level Design and type of construction
material of house/presence of domestic
animals and proximity to forested areas
Social condition Worse socio-economic status of people
in the marginalized societies and
proximity to water bodies, rubbishes,
sewerage and farms and increasing
exposure to sandﬂy/difﬁculties
accessing treatment
Environmental factors Role of vegetation area and climatic
factors in proliferation and growth
process of vector and reservoir/change
in land coverage, deforestation, forest
fragmentations, climatic variables and
temperature
Vaccines Increase in the disease incidence in
immunocompromised subjects/the
difﬁculties of epidemiological controlThe need for safe prophylactic vaccines for human and dogs
has became more important for the following reasons: 1) the
drug resistance, 2) toxicity of chemotherapy, 3) the increase of
the disease incidence in immunocompromised subjects 4) the
difﬁculties of epidemiological control based upon sacriﬁce of
seropositive dogs [116]. In spite of many vaccine candidates
identiﬁed, the poorly developed biotechnology industry and
lack of expert scientists in regulatory agencies of poor
countries contribute to the continuous use of chemotherapy.
12. Conclusion
Leishmaniasis becomes an important and opportunistic
parasitic disease after toxoplasmosis and cryptosporidiosis [64].
Risks of emergence or re-emergence of leishmaniasis are asso-
ciated with several main scenarios. The exotic Leishmania
species and strains are introduced via the increasing worldwide
travelling of humans to endemic areas and importing domestic
dogs [50,52]. The cutaneous and visceral leishmaniasis spread
naturally in the endemic regions and are transmitted to
neighboring temperate areas where there are vectors without
disease [74,117]. The re-emergence of disease has increased in
some areas such as Mediterranean region of Europe due to in-
crease in Leishmania/HIV co-infections cases that have been
observed during the recent decades (Table 1) [118]. However, for
control and prevention, concise instruments and methodologies
and expert physicians are necessary to develop surveillance
and monitoring of each risk factor.Conﬂict of interest statement
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